Abstract | A disproportionate expansion of white adipose tissue and abnormal recruitment of adipogenic precursor cells can not only lead to obesity but also impair glucose metabolism, which are both common causes of insulin resistance and diabetes mellitus. The development of novel and effective therapeutic strategies to slow the progression of obesity, diabetes mellitus and their associated complications will require improved understanding of adipogenesis and glucose metabolism. Klotho might have a role in adipocyte maturation and systemic glucose metabolism. Klotho increases adipocyte differentiation in vitro, and mice that lack Klotho activity are lean owing to reduced white adipose tissue accumulation; moreover, mice that lack the Kl gene (which encodes Klotho) are resistant to obesity induced by a high-fat diet. Knockout of Kl in leptindeficient Lep ob/ob mice reduces obesity and increases insulin sensitivity, which lowers blood glucose levels. Energy metabolism might also be influenced by Klotho. However, further studies are needed to explore the possibility that Klotho could be a novel therapeutic target to reduce obesity and related complications, and to determine whether and how Klotho might influence the regulation and function of a related protein, β-Klotho, which is also involved in energy metabolism.
Introduction
Excess adiposity is associated with the development of insulin resistance and subsequent metabolic dis orders, including type 2 diabetes mellitus (T2DM), dyslipidaemia, hypertension and coronary heart disease. [1] [2] [3] [4] [5] [6] [7] Importantly, obesity-associated disorders, including hypertension and T2DM, can partly be ameliorated by reducing body adipose content. However, inadequate amounts of adipose tissue, such as those seen in patients with lipodystrophy, can also induce the same range of metabolic complications that are observed in patients with obesity-including insulin resistance, T2DM, dyslipida emia and hepatic steatosis. 8 An adequate but not excessive amount of adipose tissue in the body is, therefore, an essential prerequisite for maintaining ph ysiological energy balance.
Despite the identification of different stages and events in adipogenesis and glucose metabolism, 9 ,10 the factors involved in the regulation of energy metabolism are not yet fully defined. A major obstacle for devel oping an effective therapy to reduce obesity and minimizing its associated complications is that crucial factors involved in energy metabolism have not yet been identified or adequately characterized in an in vivo system. Clarification of the mechanisms underlying energy metabolism is both biologically and clinically important because obesity has been identified as the second most common factor contributing to preventable death (after smoking tobacco). 9 A major research focus in the field of energy metabolism over the past decade has been the functional characterization of the peroxisome proliferator-activated receptor (PPAR) family. The nuclear receptors PPAR-α, PPAR-δ and PPAR-γ act as lipid sensors and jointly regu late the expression of several genes that are essential for the regulation of energy metabolism, although only Klotho associations with PPAR-γ have been investigated in depth. 10 PPAR-γ has been identified as a key transcriptional regulator of nutrient and energy metabolism. 11, 12 PPAR-γ also induces expression of Klotho, 13 a multifunctional protein [14] [15] [16] [17] [18] [19] involved in a number of physio logical processes and implicated in a number of diseases (Box 1). This Review examines the role of Klotho in energy metabolism and considers its contribution to adipogenesis and obesity. The effects of Klotho on glucose control and phosphate metabolism are discussed, along with the potential role of this enzyme in diabetes mellitus. The role of the related protein β-Klotho in FGF-19 and FGF-21 signalling is briefly described in the context of glucose and adipocyte turnover. Other molecular and clinical aspects of β-Klotho function are not discussed further in this article, as they have been extensively reviewed elsewhere. [49] [50] [51] [52] 
Klotho proteins
The Klotho proteins (Klotho itself and the related enzyme β-Klotho) exert diverse effects on the physio logical regulation of mineral ions (particularly calcium and phosphate) and energy metabolism by influencing the endocrine activities of fibroblast growth factors (FGFs), including FGF-19 and FGF-23. 17, 19, [51] [52] [53] [54] The Klotho protein is approximately 130 kDa with a putative signal sequence at the N-terminus, a single transmembrane domain near the C-terminus and a short (10 amino acid) cytoplasmic domain. 55, 56 The extracellular domain of Klotho consists of two internal repeats of approximately 550 amino acids each that share sequence similarity with β-glucosidase (Figure 1 ). This similarity gives Klotho a function analogous to that of β-glucosidase (albeit with weaker activity), although whether this activity occurs in vivo is not clear. 57 Both secreted and membranebound forms of Klotho can be detected in humans and other mammals. The secreted form is generated either by shedding the extracellular domain of the transmembrane protein or as a product of alternative splicing. 58 Klotho is expressed primarily in the kidney (distal convoluted tubules), parathyroid gland, brain (choroid plexus ep ithelium) 59 and adipose tissue. 60, 61 Distinguishing between the autocrine, paracrine, and endocrine actions of Klotho is often difficult because this enzyme seems to exert different functions in different cell types in a dependent or, possibly, independent manner. However, mouse genetic studies have led to the identification of a number of in vivo functions of Klotho, including roles in FGF signalling, calcium and phosphate ion transport, and energy metabolism (Box 2). 16, 17, 19, 45, Factors that induce the synthesis of the Klotho protein have not all been identified, although vitamin D seems to be an important regulator. In cells derived from the renal proximal, distal and collecting tubules, expression of Klotho (both membrane-bound and secreted splice variants) is regulated by 1,25-dihydroxyvitamin D. 82, 83 Candidate vitamin D response elements (VDREs) were identified in the vicinity of mouse and human Klotho genes, and were found to be transcriptionally active sites, as determined by reporter gene assays. 83 β-Klotho has 41% amino acid sequence similarity with Klotho and is primarily detected in the liver, pancreas, and adipose tissue. 84 β-Klotho regulates bile acid production, and mice lacking activity of this enzyme have a markedly increased synthesis and excretion of bile acids. 85 β-Klotho is also involved in FGF-21 signalling. [89] [90] [91] For example, BaF3 cells (an immortalized murine bonemarrow-derived pro-B-cell line responsive to IL-3) are unresponsive to FGF-21 exposure, but co-expression of β-Klotho and FGFR1c in FGF-21-treated BaF3 cells leads to activation of downstream signalling events resulting in phosphorylation of FGFR substrate 2α (FRS2α), MAPK 2 and MAPK 3. 91 However, unlike Fg f15 -/-mice, the pheno types of Fgf21-knockout mice 92 differ from those of β-Klotho-knockout mice. 85 Importantly, the recombinant FGF-21 protein retains its biological activity in the Klb -/-mice, suggesting the existence of a β-Klothoindependent signalling pathway involving FGF-21. 93 However, whether Klotho and β-Klotho can influence each other's functions is not yet clear.
FGF-21 can regulate insulin-independent glucose transport in adipocytes. 49 In fact, when differentiated mouse 3T3-L1 adipocytes were treated with FGF-21, uptake of glucose was stimulated, in association with increased expression of GLUT1. 94 Furthermore, systemic administration of FGF-21 to diabetic animals led to a significant reduction in blood glucose and triglyceride levels, and Fgf21-transgenic mice, which overexpress FGF-21, were resistant to obesity induced by a high-fat diet.
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Adipogenesis regulation
Adipogenesis is the process by which preadipocytes differentiate into mature adipocytes (Figure 2 ). Over the past decade, a number of important factors have been identified that contribute to the initiation and progression of adipocyte maturation. Dysregulation of these factors ■ Control of blood pressure [22] [23] [24] [25] ■ Regulation of bone mineral density 23, [26] [27] [28] [29] [30] ■ Glucose metabolism 23, 31 ■ Regulation of HDL, LDL, cholesterol and uric acid levels 21, 32 Diseases Klotho can influence in vitro adipose cell maturation by promoting differentiation of preadipocyte cells into adipocyte cells. 61 Overexpression of Klotho in 3T3-L1 cells can upregulate adipogenic factors, including PPAR-γ, FABP4 and the CCAAT-enhancer binding proteins, which initiates the maturation process. 61 Klotho expression is induced by PPAR-γ, 13 and treatment with PPAR-γ agonists (such as thiazolidinediones) increases the synthesis of both Klotho mRNA and protein in renal epithelial cell lines; this induction of Klotho can be blocked by either PPAR-γ antagonists or by silencing of PPAR-γ using small interfering RNAs. Furthermore, a noncanonical PPAR-responsive element was detected within the 5'-flanking region of the human Klotho gene, KL. Importantly, this identified site is functionally active, as demonstrated by increased transcriptional activity of a reporter gene following PPAR-γ agonist (rosiglitazone) treatment. 13 This increased activity could be abolished by a PPAR-γ antagonist (GW9662).
13 C57BL6 mice treated with thiazolidinediones demonstrated increased renal expression of Klotho, 13 and adenovirus-mediated overexpression of PPAR-γ also upregulates Klotho expres sion in the kidney. 13 Similarly, Klotho expression was reduced in the kidneys of Otsuka Long-Evans Tokushima fatty (OLETF) rats, an animal model of metabolic syndrome. How ever, treatment with troglitazone (an insulin sensitizer and PPAR-γ agonist) induced renal Klotho expression in these rats. 98 These in vitro and in vivo results sug gest that PPAR-γ increases Klotho expression, 13, 16, 99 but that Klotho can also induce PPAR-γ synthesis during adipocyte maturation. 61 Although these experimental observations are suggestive of a potential role of Klotho in adipocyte maturation, the regulatory steps of the adipocyte differentiation process that might be affected by Klotho remain to be identified, and whether Klotho can direct the commitment of multipotent mesenchymal stem cells (MSCs) to an adipogenic lineage still needs to be determined experimentally. Interestingly, stem cell transplantation can alter Klotho levels. [100] [101] [102] ■ Potassium metabolism 76 The above functions were documented in experimental studies. *The role of Klotho in FGF-23 signalling has also been validated in human studies. 45, [77] [78] [79] REVIEWS characteristic of Lep ob/ob mice. 62 In addition, a high-fat (60%) diet fed to Kl -/-mice did not lead to any gain in body weight compared with a standard-fat (20%) diet. 62 The results of this dietary manipulation study suggest that Kl -/-mice are resistant to obesity induced by a high-fat diet. 31 With our current level of understanding, it is not possible to explain the human relevance of such experimental observations. Moreover, the reader should bear in mind that animal models of diet-induced obesity are similar to, but might not always exactly mimic, human obesity. The main difference between Lep ob/ob mice and human metabolic disorders is that the Lep ob/ob mouse is a monogenic experimental model of obesity, while human metabolic disorders usually have multiple contributing factors, including genetic background, environment and dietary habits. Moreover, the homozygous Lep mutation causes early-onset morbid obesity with diabetes mellitus in mice, whereas in humans such onset could happen later in life. (Figure 3) . 62 
Glucose metabolism
The in vivo manipulation of Klotho function affects glucose metabolism; 62, 72, 73 Kl kl/kl mice have reduced pancreatic insulin content but still develop hypoglycaemia owing to increased insulin sensitivity (Figure 3) . 72 After insulin injections, blood glucose levels were markedly reduced in the Kl kl/kl mice relative to those in wild-type controls. 62, 72, 73 Transgenic mice that overexpress Kl (EFmKL46 and EFmKL48) have biochemical features of insulin resistance. 64 Low expression of Klotho in the pancreas of wild-type mice has been reported, 103 and whether such expression influences insulin production has not been shown. Furthermore, the hepatic expression of phosphoenolpyruvate carboxykinase, an enzyme that increases gluco neogenesis, was raised in the Kl kl/kl mice. 73 Nonalcoholic fatty liver disease is considered to be a hepatic manifestation of the metabolic syndrome, and is closely associated with obesity, insulin resistance, T2DM and dyslipidaemia. [107] [108] [109] Consistent with human studies, [107] [108] [109] studies in animal models of obesity and T2DM showed features of hepatic fatty changes in those animals that are similar to those seen in Lep ob/ob mice (Figure 4) ‡ P <0.05 than wild-type littermates, indicating that they have increased insulin sensitivity (100 mg/dl glucose = 5.55 mmol/l; 100 pg/ml insulin = 0.02 pmol/l).
are resistant to the development of hepatic steatosis induced by a high-fat diet. 62 Hepatic glucose synthesis also has a key role in maintaining systemic glucose metabolism. Analyses of glucose tolerance and insulin tolerance show that, compared with Lep ob/ob mice, double-mutant Kl -/-Lep ob/ob mice have greater insulin sensitivity and better glucose tolerance, which clearly suggests that Klotho has a role in the hyperglycaemia observed in Lep ob/ob mice. 62 Whether reducing Klotho activity in humans would have beneficial effects similar to those observed in Kl -/-Lep ob/ob mice is unclear and warrants further study. A report from the Centers for Disease Control showed that in 2008, approximately 68% of adults with diabetes mellitus were aged 40-64 years at diagnosis, whereas only 17% were diagnosed at age ≥65 years. 111 A study of 804 community-dwelling adults showed that serum levels of Klotho decline gradually in individuals aged ≥65 years. 112 Whether the reduction in Klotho levels observed in this age group is associated with the markedly reduced incidence of new cases of diabetes mellitus is an important area of future research with clinical and therapeutic importance.
The soluble Klotho protein does not have any effect on IGF-1 production and/or insulin signalling in HEK293, L6 and HepG2 cells, 60 and Klotho levels did not correlate with the development of insulin resistance in animal models of metabolic diseases (Wistar rats fed a high-fat diet and obese Zucker rats). 60 The mechanisms under lying the potential effects of soluble or membranebound Klotho on glucose metabolism require additional experimental clarification. An association between KL genotypes, determined by single nucleotide polymorphism analysis, and fasting levels of either high glucose or low insulin was reported in hospitalized elderly (age >65 years, mean age 79.04 ± 7.14) female patients. 113 
Phosphate metabolism
Another area that has received very little attention is the association between electrolyte homeostasis (especially of phosphate) and energy metabolism. FGF-23 is a crucial regulator of systemic phosphate metabolism, and requires Klotho to exert its effects. 15, 19, 69, [114] [115] [116] [117] [118] [119] [120] Serum phosphate levels are reduced through increased urinary excretion, which is induced by FGF-23. The presence of Klotho increases the binding affinity of FGF-23 for its receptors, 70, 71, 121, 122 which leads to phosphorylation of FGFR substrate 2, MAPK1 and MAPK2, and activation of downstream signalling events. 70, 71, [121] [122] [123] The occurrence of phosphate toxicity in Kl -/-or Kl kl/kl mice demonstrates the importance of Klotho in phosphate metabolism in vivo. 74, 103, 124, 125 Importantly, mice that lack Phex (which encodes a phosphate-regulating protein), which is homolo gous to the endopeptidase-encoding genes located on the X chromosome, have increased urinary phosphate wasting and severe hypophosphataemia owing to the increased activity of FGF-23. 74, 126, 127 However, the genetic 17, 74 In addition, a point mutation in human KL resulting in a His193Arg amino acid change in a 13-year-old patient with tumoural calcinosis was associated with significantly raised serum levels of phosphate, despite the presence of increased serum levels of FGF-23. 45 Our understanding of the critical role of the kidney in the regulation of systemic phosphate metabolism has been improved by the identification of this relationship between FGF-23 and Klotho. 19 The kidney also has an important role in maintaining systemic glucose metabolism by influencing gluconeogenesis, partly through controlling glucose filtration and reabsorption. [128] [129] [130] Further studies are needed to determine whether altered phosphate metabo lism can directly affect systemic glucose metabolism and vice-versa. Existing human studies provide some support for this association. [131] [132] [133] [134] Low serum phosphate levels are associated with reduced insulin activity. [135] [136] [137] In a study of 298 children and adolescents aged 6-12 years old, in which 190 indivi duals with obesity and 108 controls without obesity were compared, reduced phosphate serum levels were significantly associated with the develop ment of insulin resistance in children with obesity. 138 Moreover, studies in humans show that the glucose infusion rate needed to maintain hyperglycaemia (blood glucose levels 7.0 mmol/l) was 36% lower in individuals with chronic hypophosphataemia but without diabetes mellitus than in controls. Similarly, when exogenous insulin was infused at a constant rate to maintain serum insulin levels at approximately 100 μU/ml above basal levels, the glucose infusion rate required to maintain fasting glucose levels was 43% lower in hypo phosphataemic participants than in control indivi duals. 139 These results, therefore, indicate an association between an altered phosphate balance and impaired glucose metabolism in both hyper glycaemic and euglycaemic states. 139 Serum phosphate levels were positively correlated with insulin sensitivity (but not with insulin secretion) in a separate study conducted in 881 indivi duals without diabetes mellitus. 140 This corre lation was indepen dent of age, sex, proportion of body adipose content, serum calcium and serum creatinine levels. 140 Whether low insulin sensitivity and impaired glucose tolerance are the cause or the consequence of hypophosphataemia requires further investigation at the molecular level. Understanding the effects of increased serum phosphate levels on the hypoglycaemic phenotype in Kl-knockout or Kl-knockdown mice could help reveal the effects of phosphate metabolism on glucose metabolism.
Conclusions
The increasing occurrence of obesity and its related complications, including T2DM and cardiovascular anomalies, is alarming and becoming a major public health prob lem. Over the past decade, numerous in vitro and in vivo experi ments have helped to elucidate the various steps of adipose tissue remodelling that are relevant and important to human pathophysiology. Although Klotho expression is restricted to a few organs and circulating levels of this enzyme are quite low, Klotho affects numerous important biological functions, ranging from phosphate metabolism to energy metabo lism (Box 2). 16, 17, 19, 45, Dysregulation of these functions has many physiological effects and can lead to disease (Box 1). The identification of Klotho as a possible adipocyte maturation-promoting factor and its interactions with other known adipogenic factors, such as PPAR-γ and the CCAAT-enhancer binding proteins, suggest a potentially important role for Klotho in adipocyte turnover. 13, 61 However, additional studies are needed to determine the precise role of Klotho in lipid synthesis. The lean phenotype of the Kl-knockout and Kl-knockdown mice is due to reduced white adipose tissue accumulation, and their resistance to gaining body weight while on a high-fat diet implies a potential in vivo role for Klotho in adipocyte differentiation and maturation. Consistent with this observation, eliminating Klotho activity from obese Lep At present, however, whether Klotho affects the functionality of β-Klotho (which influences energy metabolism by mediating the functions of FGF-19 and FGF-21) is not clearly understood. 14, [51] [52] [53] 93 Dissociating the in vivo functions of Klotho and β-Klotho will be a challenging task, but one that could have important clinical benefits, such as enabling the development of therapies to combat obesity and its related complications.
Review criteria
PubMed was searched for original articles focussing on Klotho published from January 2000 to December 2011. The search terms used were "Klotho", "adipocyte" and "diabetes mellitus". All articles identified were Englishlanguage, full-text papers. Reference lists of identified articles were also searched for further relevant papers. The author apologises to all authors whose work could not be cited owing to space limitations. 
